Rivastigmine

Modify Date: 2024-01-02 19:44:05

Rivastigmine structure	Common Name	Rivastigmine
	CAS Number	123441-03-2	Molecular Weight	250.34
	Density	1.0±0.1 g/cm3	Boiling Point	316.2±34.0 °C at 760 mmHg
	Molecular Formula	C₁₄H₂₂N₂O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	145.0±25.7 °C

Common Name	Rivastigmine
CAS Number	123441-03-2	Molecular Weight	250.34
Density	1.0±0.1 g/cm3	Boiling Point	316.2±34.0 °C at 760 mmHg
Molecular Formula	C₁₄H₂₂N₂O₂	Melting Point	N/A
MSDS	N/A	Flash Point	145.0±25.7 °C

Purity		Quantity		Budget		Inquiry

Use of Rivastigmine

Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

Name	rivastigmine
Synonym	More Synonyms

Description	Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.
Related Catalog	Signaling Pathways >> Neuronal Signaling >> AChE Research Areas >> Neurological Disease
References	[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Description

Related Catalog

Signaling Pathways >> Neuronal Signaling >> AChE

Research Areas >> Neurological Disease

References

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.

[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.

[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.

[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Density	1.0±0.1 g/cm3
Boiling Point	316.2±34.0 °C at 760 mmHg
Molecular Formula	C₁₄H₂₂N₂O₂
Molecular Weight	250.34
Flash Point	145.0±25.7 °C
PSA	147.84000
LogP	2.14
Vapour Pressure	0.0±0.7 mmHg at 25°C
Index of Refraction	1.518

Hazard Codes	Xi

Precursor 7	Previous 1/2 Next
CAS#:42252-34-6 Ethyl(methyl)ca... CAS#:139306-10-8 3-[(1S)-1-(Dime... CAS#:856408-80-5 Carbamic acid, ... CAS#:124-40-3 Dimethylamine
CAS#:50-00-0 Formaldehyde CAS#:727418-36-2 (S)-N-ethyl-3-[... CAS#:51493-02-8 Carbamic chlori...
DownStream 3
CAS#:624-78-2 Ethylmethylamine CAS#:124-38-9 Carbon dioxide CAS#:139306-10-8 3-[(1S)-1-(Dime...